RNA sequencing of non–small cell lung cancer (NSCLC) patient-derived xenograft (PDX) tissues following chloroquine (CQ) treatment
RNA sequencing of non–small cell lung cancer (NSCLC) patient-derived xenograft (PDX) tissues following chloroquine (CQ) treatment
Th lung cancer patient-derived xenograft (PDX) models were used to measure the efficacy of the drug combination. PDX  #72-1001 were established by transplanting freshly removed tumor tissue into NSG female mouse flank subcutaneously following the protocol . Anesthetized NSG mice were inoculated with small pieces of tumor tissues (~1 mm3). Animals were treated with buprenorphine at 0.1 mg/kg for pain management. Tumor sizes were measured using a vernier caliper and the tumor volumes were calculated. Tumor size around 1200 mm3 considered as the end point for all experiments and no tumor exceeded the size in this study. At the end point, animals were sacrificed, tumors were excised and stored in liquid nitrogen with Serum-Free Cell freezing buffer.   For drug treatment: lysosome inhibitor CQ (50 mg/kg/day, i.p.) was formulated with PBS, and administrated to the mice after implantation for 2 weeks. After 2 weeks of drug treatment, all mice were euthanized, and the tissue were collected for RNA-seq.  RNA was harvested using Rneasy mini plus kit (Qiagen), 2 µg of total RNA was used for the construction of sequencing libraries. RNA libraries for RNA-seq were prepared using SMARTER Mrna-SEQ Library Prep Kit following manufactures's protocols.
European Bioinformatics Institute
E-MTAB-16128:Ctrl_2_p